In autosomal dominant polycystic kidney disease, cyst growth can enlarge the kidneys, so increasing total kidney volume provides an imaging-based sign of structural disease change. This makes the measurement useful for evaluating how the condition is progressing rather than relying only on a single clinical snapshot. It can therefore support prognosis and patient risk stratification in affected patients.
A single measurement describes renal size at one point, whereas serial total kidney volume measurements allow clinicians to compare structural status over time. That longitudinal comparison can reveal whether kidney enlargement is changing and can help assess disease progression. It also provides a basis for evaluating therapeutic effects when measurements are obtained at multiple time points.
Reliable results depend on accurately identifying the boundaries of both kidneys in the images. Each outlined region must represent the kidney tissue enclosed by its boundary before the two volumes are combined. Consistent delineation matters because the resulting value is used for comparisons over time, prognosis, risk stratification, and treatment-related assessment.
Yes. The measurement can be derived from either computed tomography or magnetic resonance images by outlining the boundaries of each kidney and calculating the enclosed volume. The choice described in the source is therefore an imaging-based workflow rather than a measurement based on external dimensions. Either approach supports quantification of renal size.
The workflow begins with CT or MRI images that display both kidneys. The boundaries of each kidney are outlined, and the enclosed volume is calculated separately for each one. Those two measurements are then summed to obtain the combined value. Repeating the same type of assessment over time enables longitudinal comparison of structural change.
Clinicians can use the measurement to support prognosis, classify patient risk, inform treatment decisions, and evaluate therapeutic effects. Its value comes from linking a quantified structural feature with change over time, particularly in autosomal dominant polycystic kidney disease, where cyst growth may enlarge the kidneys. Thus, it can contribute to both baseline assessment and follow-up of disease management.